Betta Pharmaceuticals Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Apr 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 21, 2027The maintenance fee for Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof (US 9,085,588) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Compound functioning as bromodomain protein inhibitor, and composition (US 11,845,762) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,951,959 | Glucagon-Like PEPTIDE-1 Analogues and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,409,900 | Compound for increasing kinase active and application thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,085,588 | Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,505,774 | Polymorphic forms of icotinib maleate and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,611,272 | Polymorphic forms of icotinib and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,053,238 | Benzimidazole derivatives, preparation methods and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,466,034 | Compound functioning as bromodomain protein inhibitor, and composition In force · From the USPTO record | In force | From the USPTO record | |
| US 11,845,762 | Compound functioning as bromodomain protein inhibitor, and composition In force · From the USPTO record | In force | From the USPTO record | |
| US 11,466,013 | ERK inhibitor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,043,622 | Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 1 patent in force now held by others · 9 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 1 abandoned · 26 no status recorded